The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation

[1]  S. Rosselot.  Idiopathic pulmonary fibrosis. , 2014, Nursing standard (Royal College of Nursing (Great Britain) : 1987).

[2]  Kristian Thorlund,et al.  Demystifying trial networks and network meta-analysis , 2013, BMJ.

[3]  K. Brown,et al.  Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis , 2013, Annals of Internal Medicine.

[4]  M. Horton,et al.  Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis , 2013, Annals of Internal Medicine.

[5]  A. Rahmel,et al.  The Registry of the International Society for Heart and Lung Transplantation: 29th adult lung and heart-lung transplant report-2012. , 2012, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[6]  K. Horton,et al.  Thalidomide for the Treatment of Cough in Idiopathic Pulmonary Fibrosis , 2012, Annals of Internal Medicine.

[7]  Kevin J Anstrom,et al.  Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. , 2012, The New England journal of medicine.

[8]  S. Kudoh,et al.  Efficacy of inhaled N‐acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis , 2012, Respirology.

[9]  Joyce S Lee,et al.  Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis , 2012, Thorax.

[10]  Luca Richeldi,et al.  Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. , 2011, The New England journal of medicine.

[11]  Nicky J Welton,et al.  NICE DSU Technical Support Document 2: A Generalised Linear Modelling Framework for Pairwise and Network Meta-Analysis of Randomised Controlled Trials , 2011 .

[12]  R. D. du Bois,et al.  Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. , 2011, Chest.

[13]  S. Sahn,et al.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials , 2011, The Lancet.

[14]  R. Hubbard,et al.  The rising incidence of idiopathic pulmonary fibrosis in the UK , 2011, Thorax.

[15]  Takeshi Johkoh,et al.  American Thoracic Society Documents An Official ATS / ERS / JRS / ALAT Statement : Idiopathic Pulmonary Fibrosis : Evidence-based Guidelines for Diagnosis and Management , 2011 .

[16]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[17]  H. Collard,et al.  A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. , 2010, The New England journal of medicine.

[18]  N. Kaminski,et al.  Impact of a disease-management program on symptom burden and health-related quality of life in patients with idiopathic pulmonary fibrosis and their care partners. , 2010, Heart & lung : the journal of critical care.

[19]  D. Fairclough,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2010, European Respiratory Journal.

[20]  E. Tacconelli.  Systematic reviews: CRD's guidance for undertaking reviews in health care , 2010 .

[21]  M. Eckman,et al.  Thiopurine S-Methyltranferase Testing in Idiopathic Pulmonary Fibrosis: A Pharmacogenetic Cost-Effectiveness Analysis , 2009, Lung.

[22]  G. Raghu,et al.  Pirfenidone in idiopathic pulmonary fibrosis , 2009, European Respiratory Journal.

[23]  D. Jastrzębski,et al.  [Pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis with inspiratory muscle training]. , 2008, Pneumonologia i alergologia polska.

[24]  Y. Kondoh,et al.  Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis , 2008, Respirology.

[25]  G. Oster,et al.  Incidence and prevalence of idiopathic pulmonary fibrosis. , 2006, American journal of respiratory and critical care medicine.

[26]  Johny Verschakelen,et al.  High-dose acetylcysteine in idiopathic pulmonary fibrosis. , 2005, The New England journal of medicine.

[27]  Deborah M Caldwell,et al.  Simultaneous comparison of multiple treatments: combining direct and indirect evidence , 2005, BMJ : British Medical Journal.

[28]  A. Stewart,et al.  Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives , 2005, Health and quality of life outcomes.

[29]  S. Kudoh,et al.  Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. , 2005, American journal of respiratory and critical care medicine.

[30]  M Sculpher,et al.  Health Technology Assessment: Development and Future , 2009 .

[31]  M Sculpher,et al.  A pilot study on the use of decision theory and value of information analysis as part of the NHS Health Technology Assessment programme. , 2004, Health technology assessment.

[32]  Disciplinary Committee,et al.  Royal Pharmaceutical Society of Great Britain , 2002 .

[33]  A. Mcguire,et al.  Assessment of quality of life in lung transplantation using a simple generic tool , 2001, Thorax.

[34]  S. Chinn.  A simple method for converting an odds ratio to effect size for use in meta-analysis. , 2000, Statistics in medicine.

[35]  T O Jefferson,et al.  Guidelines for authors and peer reviewers of economic submissions to the BMJ , 1996, BMJ.

[36]  A. B. Prasad,et al.  British National Formulary , 1994 .

[37]  G. Raghu,et al.  Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: a prospective double-blind, randomized, placebo-controlled clinical trial. , 1991, The American review of respiratory disease.